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Abstract. Drug-resistant Plasmodium falciparum is present in Vietnam. We assessed the in vivo sensitivity of P.
falciparum to halofantrine in two villages in the southern part of central Vietnam. Halofantrine (8 mg/kg × 3 doses) was
administered to 37 patients with either P. falciparum (n  32) or mixed P. falciparum/P. vivax malaria (n  5). End
points were parasite sensitivity or resistance (RI/RII/RIII) determined by parasite clearance, persistence, or recurrence
during 28 days of follow-up. By day 28, 31 (93.9%) of 33 (95% confidence interval  79.8−99.2%) patients were
sensitive. Two patients had recurrent P. falciparum parasitemia on days 14 and 21. Halofantrine effectively treated
uncomplicated P. falciparum malaria in these Vietnamese patients.
In Vietnam, Plasmodium falciparum is resistant to com-
monly used antimamalarial drugs.1 In 1995, we investigated
the sensitivity of halofantrine by conducting a 28-day in vivo
test in two villages in Khanh Hoa province, 40 miles west of
the coastal town of Nha Trang in southern central Vietnam.
Malaria incidence rates in this area are 1.9 per person-year for
P. falciparum, 1.1/person-year for P. vivax, and 0.03/person-
year for P. malariae (Nhan DH, unpublished data). Written,
informed consent was obtained from all participating patients
or their parents/guardians. The study was conducted accord-
ing to the Vietnamese Ministry of Health and the United
States Navy regulations governing the protection of human
subjects in medical research. Entry criteria and study conduct
have been reported in detail elsewhere.2 Three doses of ha-
lofantrine (Glaxo SmithKline, London, United Kingdom), 8
mg/kg every six hours, was administered in the hospital on an
empty stomach (at least one hour before or two hours after a
meal) to patients with no clinical signs of cardiac disease
and a normal QTc interval. Thick and thin film blood
smears (days 1, 2, 4, 7, 11, 14, 18, 21, and 28) were stained
with Giemsa, read, and the results were reported as para-
sites/microliter. Data were analyzed using Epi-Info version
6.04 (Centers for Disease Control and Prevention, Atlanta,
GA).
There were 37 treated patients in the study: 32 with P.
falciparum monoinfection and 5 with mixed P. falciparum/P.
vivax malaria. Enrollment characteristics are shown in Table
1. On day 0, all patients were either symptomatic or febrile
(oral temperature > 37°C). By day 28, four patients were lost
to follow-up, and two patients with P. falciparum malaria
developed recurrent P. falciparum parasitemia: a 17-year-old
man on day 14 (day 0 parasitemia  2,120/L, recurrent
parasitemia  240/L) and an eight-year-old girl on day 21
(day 0 parasitemia  18,040/L, recurrent parasitemia 
280/L). Using a previously published method,3 we amplified
the small subunit ribosomal RNA of P. falciparum by a poly-
merase chain reaction (PCR) to confirm the microscopic di-
agnosis of P. falciparum of the day 0/day recurrent (dayrec)
slides. However, technical difficulties unfortunately pre-
cluded the genotyping the dayrec slides with merozoite surface
protein-2 primers.3 When the four patients lost to follow-up
were excluded, the 28-day cure rate was 31 (93.9%) of 33
(95% confidence interval  79.8−99.2%). The P. falciparum
parasite clearance rates were 16.2% by day 1, 73.0% by day 2,
91.4% by day 4, and 100% by day 7.
This study demonstrates the sensitivity of P. falciparum to
halofantrine in one small area of southern central Vietnam.
Recurrent parasitemia (n  2) occurred on days 14 and 21,
consistent with new infections, RI resistance, or treatment
failures due to poor absorption of halofantrine.4 The ex-
pected number of new P. falciparum infections in our cohort
of 33 who completed the four week follow-up is ≈5 (1.9 in-
fections/person-year × 33 persons × 4 weeks × 1/52 years).
These epidemiologic data favor new infections as the cause of
our two cases of recurrent parasitemia. However, we cannot
exclude drug resistance because of the failure of our PCR
genotyping.
Mefloquine, but not halofantrine, was available in local
shops when the study was conducted. Mefloquine is cross-
resistant to halofantrine; thus, its use would be a factor in the
generation of halofantrine resistance.5,6 Our study used the
original World Health Organization (WHO) parasitologic in
vivo test to assess halofantrine sensitivity. There is now a new
WHO in vivo test for areas of intense and low/moderate ma-
laria transmission that should be adopted as the standard test
for defining drug resistance. Accordingly, our two cases of
recurrent parasitemia would have been classified as either
late parasitologic or clinical treatment failures, depending on
whether they were febrile (axillary temperature  37.5°C.) at
the time of their recurrent parasitemia.7
TABLE 1
Enrollment characteristics of Vietnamese patients with Plasmodium
falciparum (n  32) or mixed P. falciparum/P. vivax (n  5) ma-
laria in a 28-day in vivo test assessing halofantrine sensitivity
Halofantrine group
(n  37)
No. (%) of males 23 (62.2)
Median (range) age in years 12 (5–42)
Prestudy antimalarial drug use* 13 (35.1)
No. (%) symptomatic† 28 (75.7)
No. (%) febrile‡ 31 (83.8)
Median (range) day 0 temperature, °C 37.5 (36.3–39.5)
No. (%) with splenomegaly 24 (64.9)
Median (range) P. falciparum parasitemia/L 400 (40–46,480)
* Number (%) consuming any antimalarial drug within one month of enrollment.
† Defined as fever, chills, headache, myalgia, or anorexia.
‡ Defined as an oral temperature > 37.0°C.
Am. J. Trop. Med. Hyg., 69(5), 2003, pp. 553–554
553
Halofantrine has potentially serious cardiotoxicity that re-
stricts its use to specific clinical indications, e.g., drug-resistant
P. falciparum malaria in patients with normal electrocardio-
graphic findings who have not recently consumed drugs that
prolong the QTc interval.8−10 These prerequisites make ha-
lofantrine unsuitable for widespread use in primary health
settings of malaria-endemic countries.
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